Long-term treatment with antipsychotic drugs in patients with schizophrenia can lead to dopamine supersensitivity psychosis. It is reported that repeated administration of haloperidol caused dopamine supersensitivity in rats. Blonanserin is an atypical antipsychotic drug with high affinity for dopamine D 2 , D 3 and serotonin 2A receptors. In this study, we investigated whether chronic administration of blonanserin leads to dopamine supersensitivity. Following oral treatment with blonanserin (0.78 mg/kg) or haloperidol (1.1 mg/kg) twice daily for 28 days, the dopamine D 2 agonist quinpirole-induced hyperlocomotion test and a dopamine D 2 receptor binding assay were conducted. We found that haloperidol significantly enhanced both quinpirole-induced hyperlocomotion and striatal dopamine D 2 receptor density in rats. On the other hand, repeated administration of blonanserin had no effect on either locomotor activity or striatal dopamine D 2 receptor density. Further, our results show that mRNA levels of dopamine D 2 and D 3 receptors in several brain regions were unaffected by repeated administration of both agents. In addition, we examined the effect of the dopamine D 3 receptor antagonist PG-01037 on development of dopamine supersensitivity induced by chronic haloperidol treatment and showed that PG-01037 prevents the development of supersensitivity to quinpirole in chronic haloperidol-treated rats. Given the higher affinity of blonanserin at dopamine D 3 receptors than haloperidol, antagonism of blonanserin at dopamine D 3 receptors may play a role in lack of dopamine supersensitivity after chronic administration. The present findings suggest long-term treatment with antipsychotic dose of blonanserin may be unlikely to lead to dopamine supersensitivity.
Introduction
Antipsychotics that act as dopamine D 2 receptor antagonists are the most commonly prescribed drugs for schizophrenia and are known to exert sufficient therapeutic effect on acute symptoms of schizophrenia. However, chronic treatment with dopamine D 2 receptor antagonists can induce dopamine supersensitivity psychosis (DSP) in patients with schizophrenia (Chouinard, 1991; Chouinard et al., 1988) . DSP is characterized by acute exacerbation of psychotic symptoms following treatment dose reduction or discontinuation, relapse after minor stress, tolerance to previously observed therapeutic effects, and co-occurring tardive dyskinesia (Iyo et al., 2013; Seeman and Seeman, 2014) . Although the exact pathogenic mechanism of DSP is still unclear, it is considered that DSP is closely associated with compensatory up-regulation of dopamine D 2 receptors following prolonged and excessive blockade of this receptor (Samaha et al., 2008 (Samaha et al., , 2007 .
Blonanserin is an atypical antipsychotic with high affinity for the dopamine D 2 L receptor (K i ; 0.284 nM), dopamine D 3 receptor (K i ; 0.277 nM) and serotonin 2A (5-HT 2A ) receptor (K i ; 0.640 nM) (Baba et al., 2015; Murasaki et al., 2008) . BNS is approved for the treatment of schizophrenia in Japan, South Korea and China (Deeks and Keating, 2010; Li et al., 2015) . Compared to haloperidol, blonanserin has superior clinical efficacy on schizophrenia negative symptoms with lower risk of akathisia (Kishi et al., 2013) . Besides, various studies in animal models of schizophrenia symptoms suggest that blonanserin can ameliorate both positive and negative symptoms, including cognitive impairment associated with schizophrenia (Kotani et al., 2016; Nagai et al., 2003; Oka et al., 1993) . Interestingly, although blonanserin binding affinity for the dopamine D 2 receptor is higher than that of haloperidol (Murasaki et al., 2008) , blonanserin is reported to exhibit lower risk of catalepsy in rodents . Furthermore, in our previous study using a possible animal model of tardive dyskinesia, chronic administration of blonanserin, unlike haloperidol, had no effect on SKF38393 (a dopamine D 1 receptor agonist)-induced oral activity enhancement, suggesting that chronic treatment with blonanserin does not induce tardive dyskinesia-like symptoms, which often co-occur with dopamine supersensitivity .
In order to further elucidate the difference between blonanserin and haloperidol in the development of dopamine supersensitivity, we conducted the dopamine D 2 agonist quinpirole-induced hyperlocomotion test and a striatal dopamine D 2 receptor binding assay in rats following repeated administration of blonanserin or haloperidol. In addition, we determined mRNA levels of dopamine D 2 and D 3 receptors in several brain regions of these experimental rats. Blonanserin exhibited almost equal affinities for dopamine D 2 and D 3 receptors (D 2 /D 3 K i ratio, 1.025) (Baba et al., 2015) , while haloperidol had higher affinity for dopamine D 2 receptors than D 3 receptors (D 2L K i , 2.34 nM; D 3 K i , 12 nM; D 2 /D 3 K i ratio, 0.195) (Richtand et al., 2007) . Hence, development of dopamine supersensitivity may be suppressed if affinity of haloperidol for D 3 receptors is higher than the actual affinity. To investigate this, we used the quinpirole-induced hyperlocomotion test following continuous co-administration of haloperidol and a dopamine D 3 receptor antagonist.
Materials and methods

Animals
Male Wistar rats were purchased from CLEA Japan, Inc. (Japan). The animals were housed in plastic cages (4 rats/cage) maintained in a temperature (23 ± 3°C)-and humidity (55 ± 15%)-controlled animal room under a 12/12 h light/dark cycle (light on at 07:00). The animals had free access to food and water and were acclimatized for at least seven days before the initiation of test-drugs administration. Altered dopaminergic systems in rat brain during adolescence are reported (Spear, 2000) . In our present study, the repeated or continuous administration of drugs were started during mid-adolescence. All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Sumitomo Dainippon Pharma Co., Ltd.
Drugs
Haloperidol, blonanserin and methamphetamine were synthesized in Sumitomo Dainippon Pharma Co., Ltd (Osaka, Japan). (-)-Quinpirole hydrochloride and PG-01037 dihydrochloride were purchased from Tocris Bioscience (Bristol, UK). [ 3 H]Raclopride (76.0 Ci/mmol) was purchased from PerkinElmer Japan (Yokohama, Japan). Other chemicals were purchased commercially. Blonanserin and haloperidol were suspended in 0.5% methylcellulose (MC), which served as vehicle for oral administration. Haloperidol and PG-01037 were dissolved in 2% glacial acetic acid/H 2 O solution (pH adjusted to 3.6 with NaOH) containing 0.5% Tween 80 for continuous Alzet osmotic minipump (model 2ML2; DURECT corp., USA) administration. Methamphetamine and quinpirole were dissolved in physiological saline.
Methamphetamine-induced hyperlocomotion test
Methamphetamine-induced hyperlocomotion test was performed to determine haloperidol and blonanserin ED 50 values for induction of antipsychotic-like effect in rats. Rats (8 weeks old) were orally given vehicle, haloperidol (0.1-3 mg/kg) or blonanserin (0.1-3 mg/kg) 60 min before subcutaneously injection of methamphetamine (1 mg/ kg). The rats were then individually placed in a top-opened plastic box (438 × 438 × 295 mm), and locomotor activity was measured for 60 min using an automated system (SCANET MV-40) (Melquest Ltd., Toyama, Japan).
Oral drug administration and tissue collection
Animals (6 weeks old) were assigned to three groups, i.e. vehicletreated group, haloperidol-treated group and blonanserin-treated group. They were then orally administered haloperidol (1.1 mg/kg), blonanserin (0.78 mg/kg) or vehicle twice daily (between 8:00 and 9:00 and between 18:00 and 19:00) for 28 days in a dosing volume of 5 ml/ kg. The doses of haloperidol and blonanserin were determined, based on the results of methamphetamine-induced hyperlocomotion test, as twice the ED 50 of each drug antipsychotic-like effect in rats. Seven days after the last administration, the animals were used in a quinpiroleinduced hyperlocomotion test or decapitated to collect the striatum for radioligand binding assay. The obtained striatum samples were frozen in dry ice powder and stored at − 80°C until use. For mRNA quantification experiment, the animals (6 weeks old) were given each drug twice daily for 28 days and decapitated 4 h after morning administration of haloperidol, blonanserin, or vehicle on Day 29. Their brains were quickly dissected into 5 regions: prefrontal cortex, striatum, nucleus accumbens, hippocampus and cerebellar lobes 9 and 10 (L9/10). The obtained brain samples were stored in RNAlater solution at − 20°C until use. Animals decapitation time (i.e. 4 h after test drugs last administration) was chosen based on a report showing that repeated administration of haloperidol alter dopamine receptor mRNA (D'Souza et al., 1997).
Continuous osmotic minipump administration
Animals (7 weeks old) were assigned to four groups, i.e. vehicletreated group, haloperidol-treated group, PG-01037-treated group, and HPD plus PG-treated group. An Alzet osmotic minipump containing either vehicle (2% glacial acetic acid/H 2 O solution), haloperidol (0.75 mg/kg/day), PG-01037 (0.6 mg/kg/day) or haloperidol plus PG-01037 was then implanted into each animal under isoflurane inhalational anesthesia. Briefly, a 1.5 cm-wide incision was made in each animal's lower back, and forceps were used to loosen the connective tissue between the scapulae. The minipump was inserted to lie on the right side of the scapula with its flow moderator pointed away from the incision. The incision was then closed using 9 mm surgical staples and treated with antibiotics. All minipumps were removed 14 days after implantation, and the animals were used for quinpirole-induced hyperlocomotion test 7 days after minipumps extraction. The doses of haloperidol and PG-01037 were selected based on the results of our previous report (Oda et al., 2015) and on those of our preliminary experiments, respectively.
Quinpirole-induced hyperlocomotion test
Seven days after repeated oral administration or continuous osmotic minipump administration, the rats were individually put in a topopened plastic box (438 × 438 × 295 mm) and habituated for 60 min. After habituation, each rat was subcutaneously injected with quinpirole (0.5 mg/kg) and immediately returned to the box. Locomotor activity was measured using an automated system (SCANET MV-40) (Melquest Ltd., Toyama, Japan) every 10 min starting 30 min before quinpirole injection until 60 min after quinpirole injection. The dose of quinpirole was selected based on information in the literature (Lau et al., 2003) .
Radioligand binding assay
The radioligand binding assay for striatal dopamine D 2 receptors was performed as described in our previous report (Oda et al., 2015) . Briefly, each frozen striatal sample was homogenized in 50 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing 120 mM NaCl and 5 mM KCl (assay buffer) and then centrifuged at 40,000 ×g for 15 min at 4°C. The pellet was suspended in assay buffer, centrifuged, resuspended in assay buffer and centrifuged again. Finally, the pellet was suspended in 2.6 ml assay buffer.
Next, the membrane homogenate (100 μl) was added to a tube containing 50 μl of [ 3 H]raclopride, and the mixture was supplemented with assay buffer to a final volume of 500 μl. After incubation of the homogenate with increasing concentrations (0.25, 0.5, 1, 2, 4 and 8 nM) of [ 3 H]raclopride, for 60 min at 25°C, the reaction mixture was rapidly filtered through a Whatman GF/B glass filter pretreated with 0.5% polyethyleneimine for at least 2 h using a Brandell 24-channel cell harvester (Neuroscience, Inc., Tokyo, Japan). Finally, the filter was rinsed twice with 4 ml ice-cold 50 mM Tris-HCl buffer (pH 7.4). Nonspecific binding was determined in the presence of 300 µM (-)-sulpiride, and the radioactivity was determined using a liquid scintillation counter. Protein concentration in the reaction mixture was determined according to the method of Lowry et al. (1951) . All experiments were performed in duplicate. B max and K d values for dopamine D 2 receptors in each rat were calculated by a nonlinear regression curve fit using GraphPad Prism 5.01 software for Windows.
Quantification of mRNA
Total RNA was isolated from each brain tissue sample using RNeasy Mini kit (catalog #74104, QIAGEN Inc., CA, USA). The experimental procedure followed the instructions manual provided by the manufacturer. The concentration of RNA was determined with a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc., MA, USA). mRNA samples were stored at − 80°C until use.
Reverse transcription reaction was performed with a Gene Amp PCR System 9600 (Applied Biosystems, CA, USA). The reaction solution containing 25 μl RT-buffer (2 ×), 2.5 μl RT Enzyme Mix (20 ×) (catalog #4399003, TaqMan Fast cells to C T Kit, Thermo Fisher Scientific) and 22.5 μl of sample (about 1 ng of mRNA) was incubated at 37°C for 60 min and at 95°C for 5 min, and then cooled on ice.
Real-time RT-PCR was performed with an Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems) as follows: 20 s at 95°C followed by 40 cycles of 3 s at 95°C and 30 s at 60°C. Each reaction was carried out in a total volume of 20 μl, consisting of 10 μl TaqMan Fast Universal PCR Master Mix (catalog #4399003, TaqMan Fast cells to C T Kit, Thermo Fisher Scientific), 1 μl of Eukaryotic 18 S rRNA Endogenous Control (VIC) (catalog #4319413E, Applied Biosystems), 1 μl of each primer, 4 μl of distilled water and 4 μl of cDNA. The primers were purchased from Applied Biosystems (TaqMan Gene Expression Assays (FAM)); Dr2 (Rn00561126-m1) and Dr3 (Rn00567568-m1). Expression data were analyzed with the High Resolution Melt Software v2.0 (Applied Biosystems).
Statistical analysis
All data are expressed as mean and standard error of the mean (S.E.M.). Each drug ED 50 value and its 95% confidence interval for antipsychotic-like effect were estimated by the non-linear regression according to the logit model using SAS Enterprise Guide 4.1 (SAS Institute Japan, Ltd., Tokyo, Japan). Statistical analysis was performed using the SAS ® system (version 9.2, SAS Institute Japan, Ltd., Tokyo, Japan). In the quinpirole-induced hyperlocomotion test, one-way analysis of variance (ANOVA) followed by Dunnett's test was conducted to compare locomotor activity between 30 10-min block (i.e. locomotor activity for 10 min before quinpirole injection) and each 10-min block after quinpirole injection. The effects of repeated administration of vehicle, haloperidol and blonanserin, or the effects of continuous administration of vehicle, haloperidol, PG-01037 and haloperidol plus PG-01037 on time-dependent change of locomotor activity were analyzed by repeated measures two-way ANOVA. When a significant effect was found, post hoc Tukey-Kramer's test was conducted to compare differences among repeated vehicle-, haloperidol-and blonanserin-treated groups or chronic vehicle-, haloperidol-, PG-01037-, and haloperidol plus PG-01037-treated groups in each 10-min block. In order to assess the effects of repeated administration of haloperidol or blonanserin on quinpirole-induced hyperlocomotion, mean total locomotor activity for 60 min (in the repeated oral administration experiment) or 30 min (in the continuous osmotic minipump administration experiment) after quinpirole injection were analyzed by one-way ANOVA followed by Tukey-Kramer's test. To assess the effect of continuous PG-01037 treatment on haloperidol-induced supersensitivity to quinpirole, mean total locomotor activity for 30 min after quinpirole injection was analyzed by one-way ANOVA followed by Tukey-Kramer's test. The data of radioligand binding assay were analyzed by one-way ANOVA followed by Tukey-Kramer's test. Quantification data of mRNA levels were analyzed statistically by one-way ANOVA. Values of P < 0.05 (two-tailed test) were considered as statistically significant.
Results
Methamphetamine-induced hyperlocomotion test
Haloperidol and blonanserin ED 50 values for inhibition of methamphetamine-induced hyperlocomotion were 0.55 mg/kg (95% confidence limits; 0.40-0.76) and 0.39 mg/kg (95% confidence limits; 0.31-0.49), respectively (Fig. 1) .
Effects of repeated administration of haloperidol or blonanserin on quinpirole-induced hyperlocomotion
One of the main objectives of the present study was to investigate whether repeated administration of haloperidol or blonanserin affects quinpirole-induced hyperlocomotion. As shown in Fig. 2A , quinpirole at 0.5 mg/kg (s.c.) increased locomotor activity in rats. One-way ANOVA revealed a significant effect of quinpirole on locomotion compared to the vehicle-treated rats (F 6,105 = 8.77, P < 0.001). Post-hoc Dunnett's test showed that locomotor activity in all 10-min blocks after quinpirole injection was significantly higher than that in 30 10-min block (i.e. locomotor activity for 10 min just before quinpirole injection). Twoway repeated measured ANOVA revealed significant effects of both treatment groups (F 2,299 = 20.30, P < 0.001) and time-blocks (F 6,299 = 10.90, P < 0.001). Based on post hoc analysis, quinpirole-induced hyperlocomotion was significantly enhanced by treatment with haloperidol in both the 60 and 80 10-min blocks as compared to treatment with vehicle being (Fig. 2A) . As for total locomotor activity, one-way ANOVA revealed a significant difference among treatment groups after quinpirole injection (F 2,41 = 5.19, P < 0.01, Fig. 2B ). Repeated administration of haloperidol significantly enhanced total quinpirole-induced hyperlocomotion for 60 min after quinpirole injection (Fig. 2B) . Fig. 1 . Inhibitory effects of haloperidol and blonanserin on methamphetamineinduced hyperlocomotion in rats. Vehicle, haloperidol (HPD) or blonanserin (BNS) was orally given to rats 60 min before subcutaneous injection of methamphetamine (MAP) (1 mg/kg). The rats locomotor activity was measured for 60 min after MAP injection. All data represent the mean ± S.E.M. N = 6-8.
On the other hand, total locomotor activity in the blonanserin-treated group after quinpirole injection was almost the same as that in the vehicle-treated group, but significantly lower than that in the haloperidol-treated group (Fig. 2B) . These results suggest that unlike haloperidol, blonanserin is less likely to induce dopamine supersensitivity upon repeated administration.
Effects of repeated administration of haloperidol or blonanserin on striatal D 2 receptor binding
The effects of repeated administration of haloperidol or blonanserin on striatal dopamine D 2 receptors density and binding were evaluated in a [ 3 H]raclopride binding experiment using Scatchard analysis. Oneway ANOVA revealed a significant difference in B max value among the vehicle-, haloperidol-, and blonanserin-treated groups (F 2,21 = 7.82, P < 0.01). Post-hoc Tukey-Kramer's test showed that B max value (346.3 ± 12.9 fmol/mg protein) in the haloperidol-treated group was significantly higher than in the vehicle-treated group (274.8 ± 6.6 fmol/mg protein) (P = 0.002), whereas there was no significant difference in B max value between the blonanserin-treated group (312.1 ± 16.8 fmol/mg protein) and the vehicle-treated group (P = 0.122) (Fig. 3A) . This suggests that blonanserin is less likely to induce up-regulation of dopamine D 2 receptors than haloperidol. As for K d value of striatal dopamine D 2 receptor (vehicle-treated group, 0.31 ± 0.017 nM; haloperidol-treated group, 0.35 ± 0.017 nM; blonanserin-treated group, 0.33 ± 0.011 nM), one-way ANOVA revealed no statistical significance among the three groups (F 2,21 = 1.16, P = 0.332; Fig. 3B ).
Effects of repeated administration of haloperidol or blonanserin on mRNA levels of dopamine D 2 and D 3 receptors in several regions of the rat brain
Our investigation covered the prefrontal cortex, striatum, nucleus accumbens, hippocampus and cerebellar L9/10. One-way ANOVA revealed that relative mRNA expression levels of dopamine D 2 (Fig. 4A ) and D 3 receptors (Fig. 4B ) in each brain region were not statistically different among the three experimental groups (vehicle group, haloperidol group, and blonanserin group).
Effects of the dopamine D 3 receptor antagonist PG-01037 on QPRinduced hyperlocomotion in rats
Treatment with QPR increased rats locomotor activity, and continuous minipump administration of HPD for 14 days enhanced the effect of QPR. Moreover, one-way ANOVA revealed a significant effect of quinpirole on rats locomotor activity compared to the vehicle-treated rats (F 9,80 = 6.11, P < 0.001). Post-hoc Dunnett's test showed that Fig. 2 . Effects of repeated administration of haloperidol or blonanserin on quinpirole-induced hyperlocomotion in rats. A: time-dependent change in locomotor activity before and after treatment with quinpirole (QPR) in vehicle (VEH)-, haloperidol (HPD)-or blonanserin (BNS)-treated rats. B: total locomotor activity for 60 min after QPR injection. VEH (0.5% MC solution), HPD (1.1 mg/kg) or BNS (0.78 mg/kg) was orally given to rats twice daily for 28 days, and rats locomotor activity was assessed 7 days after the last administration. Rats were put in the test box 60 min before QPR injection (0.5 mg/kg, s.c.), and locomotor activity was measured starting 30 min before QPR injection until 60 min after QPR injection (90 min in total). All data represent the mean ± S.E.M. VEH-or BNS-treated group; n = 16. HPD-treated group; n = 12 (4 rats were excluded from analysis, because they escaped from the test box after QPR injection). #P < 0.05, ##P < 0.01: vs. the 30 10-min block (Dunnett's test). ** P < 0.01: vs. VEH-treated group in each 10-min block (Tukey-Kramer's test). †P < 0.05: VEH-treated group vs. HPD-treated group and HPD-treated group vs. BNS-treated group (Tukey-Kramer's test). locomotor activity from the 50 to the 90 10-min block was significantly higher than that in the 30 10-min block (i.e. locomotor activity for 10 min just before quinpirole injection). Two-way repeated measures ANOVA revealed significant effects of both treatment groups (F 3,256 = 6.79, P < 0.001) and time-blocks (F 6,256 = 12.01, P < 0.001). Post hoc analysis revealed that quinpirole-induced hyperlocomotion from 40 to 60 10-min blocks was significantly enhanced in haloperidol-treated group. However, in the rats that received concomitant administration of haloperidol and PG-01037, quinpirole-induced hyperlocomotion was almost the same as that in the vehicle-treated group, except for the 40 10-min block (Fig. 5A) . Continuous minipump administration of PG-01037 alone had no effect on quinpirole-induced hyperlocomotion. As for total locomotor activity, one-way ANOVA revealed a significant difference among the groups after quinpirole injection (F 3,34 = 6.21, P < 0.01, Fig. 5B ). Post-hoc analysis revealed that animals in the haloperidol-treated group showed significantly enhanced total quinpiroleinduced hyperlocomotion for 30 min after quinpirole injection (Fig. 5B) . On the other hand, PG-01037 alone or in combination with haloperidol had no effect on total locomotor activity in quinpiroletreated rats (Fig. 5B) . These results suggest that high antagonism of dopamine D 3 receptors may contribute to suppression of dopamine supersensitivity with chronic administration of antipsychotics.
Discussion
To elucidate the difference between blonanserin and haloperidol in the development of dopamine supersensitivity, we conducted quinpirole-induced hyperlocomotion test and a striatal dopamine D 2 receptor binding assay following repeated administration of blonanserin or haloperidol. As reported in the literature, repeated administration of haloperidol significantly enhanced both quinpirole-induced hyperlocomotion and striatal dopamine D 2 receptor density in rats (Lau et al., 2003) . On the other hand, repeated administration of blonanserin prevented development of supersensitivity to quinpirole and did not increase striatal dopamine D 2 receptor levels. These results suggest that chronic treatment with blonanserin is unlikely to induce dopamine supersensitivity.
Repeated administration of haloperidol at twice its ED 50 value, as determined in the methamphetamine-induced hyperlocomotion test, induced supersensitivity to quinpirole in rats, whereas similar treatment with blonanserin had no such effect. According to our previous in vivo binding assay for dopamine D 2 receptors (Baba et al., 2015) and preliminary data, dopamine D 2 receptor occupancy by haloperidol and blonanserin is estimated to be 99.8% and 92.9%, respectively, at 2 h after oral administration of the current doses. These levels are assumed to exceed clinically optimal D 2 receptor occupancy for at least several hours. Samaha et al. (2007) have demonstrated that continued administration of haloperidol induces dopamine supersensitivity in rats and that the dose of haloperidol used achieved more than 80% dopamine D 2 receptor occupancy in the striatum. Taken together, these findings suggest that blonanserin is unlikely to cause dopamine supersensitivity in clinical use.
A number of studies in animals and humans have shown that the , PG (0.6 mg/kg/day) or HPD plus PG were continuously administered via an osmotic minipumps to rats for 14 days, and the effects of these test drugs on QPR-induced hyperlocomotion were assessed 7 days after extirpation of the minipumps. All data represent the mean ± S.E.M. VEH-and HPD-treated group; n = 9. PG-and HPD plus PGtreated group; n = 10. #P < 0.05, ##P < 0.01: vs. the 30 10-min block (Dunnett's test). * P < 0.05, * * P < 0.01: vs. VEH-treated group in each 10-min block (Tukey-Kramer's test). † †P < 0.01, †P < 0.05: VEH-treated group vs. HPD-treated group and HPD-treated group vs. HPD plus PG-treated group (Tukey-Kramer's test).
long-term treatment with antipsychotics increases striatal dopamine D 2 receptor density and that this increased density presumably associated with the development of dopamine supersensitivity (Chouinard et al., 1986; Huang et al., 1997; Inoue et al., 1997; Iyo et al., 2013; Köhler et al., 1994; Samaha et al., 2007; Silvestri et al., 2000) . Indeed, it has been reported, as shown in this study, that repeated administration of haloperidol induces dopamine supersensitivity (Köhler et al., 1994; Samaha et al., 2007) and increases striatal dopamine D 2 receptor density by 1.2-1.4-fold (Huang et al., 1997; Inoue et al., 1997; Köhler et al., 1994; Samaha et al., 2007) . On the other hand, repeated treatment with blonanserin neither induce supersensitivity to quinpirole nor increase striatal dopamine D 2 receptor density in this study, suggesting these effects may be unique to blonanserin. Seeman (2011) have reported that, in the striatum of dopamine supersensitive rats, the density of high-affinity state dopamine D 2 (D 2 High ) receptors is more variable than total dopamine D 2 receptors. Therefore, further understanding the difference between haloperidol and blonanserin in the development of dopamine supersensitivity requires investigation of the density of D 2
High receptors, although D 2 High levels are not reliably associated with antipsychotic-induced dopamine supersensitivity (Samaha et al., 2008) . In the present study, repeated administration of haloperidol and blonanserin did not affect mRNA levels of dopamine D 2 and D 3 receptors in all five investigated brain regions. Although a number of studies have investigated mRNA levels of dopamine receptors in the brains of rats treated with antipsychotics (Fishbum et al., 1994; Goss et al., 1991; Rogue et al., 1991; Srivastava et al., 1990) , whether dopamine receptor mRNA levels are increased by repeated treatment with antipsychotics is still controversial. When D 'Souza et al. (1997) reviewed 23 reports on changes in mRNA levels following repeated treatment with antipsychotics, they found that 15 reports describe upregulation of mRNA levels and 8 reports indicate no change. Consequently, they concluded that three factors affect dopamine receptor mRNA levels, i.e. the drug dosage, the exposure time and the kind of drug. In order to evaluate the effect of repeated administration of haloperidol on mRNA levels, we selected in this study the same dosing and sacrificing schedule as that described by D 'Souza et al. (1997) , although the dosage and starting age of repeated administration were slightly different from D'Souza's experiment. Further, some studies have reported that repeated haloperidol administration increases mRNA levels of dopamine D 2 receptors in rats that are almost the same age as those used here (Bernard et al., 1991; Lévesque et al., 1995) . Therefore, we assume that the dosing schedule used in our study, i.e. twice the ED 50 value for 28 days, may not provide reliable information on mRNA levels, although it is very much adequate for collecting information on changes in D 2 receptor density. Further experiments are needed to clarify whether repeated administration of blonanserin affects mRNA levels of brain dopamine receptors.
Chronic antipsychotic treatment increases striatal dopamine D 2 receptor density in animals and patients with schizophrenia (Burt et al., 1977; Mackay et al., 1982; Silvestri et al., 2000) . Indeed, dopamine D 2 receptor up-regulation is considered to be one of the causes for development of tardive dyskinesia in humans (Chouinard and Jones, 1980) , and in some cases can lead to dopamine supersensitivity (Samaha et al., 2008 (Samaha et al., , 2007 . Excessive blockade of striatal dopamine D 2 receptors (≥ 80% D 2 receptor occupancy) induces extrapyramidal side effects such as catalepsy, which can be a predictor for development of tardive dyskinesia (Chouinard et al., 1988; Iyo et al., 2013) . Atypical antipsychotics are characterized by higher affinity for 5-HT 2A receptors than dopamine D 2 receptors (Seeman, 2011) . Certainly, this char risk for induction of extrapyramidal side effects. In fact, several studies have suggested that blockade of 5-HT 2A receptors attenuates chronic haloperidol-induced dopamine D 2 receptor up-regulation and dopamine supersensitivity (Charron et al., 2015; Ishikane et al., 1997) . In contrast, continuous administration of the atypical antipsychotics, risperidone or olanzapine, induced dopamine supersensitivity (Gao and Li, 2013; Samaha et al., 2007) . Consequently, we inferred that involvement of 5-HT 2A receptor antagonism alone may be insufficient to suppress development of dopamine supersensitivity. Several reports have shown that blockade of dopamine D 3 receptor contributes to the reduction of extrapyramidal side effects caused by haloperidol, suggesting that dopamine D 3 receptor antagonism may relieve the excessive inhibition of dopamine D 2 receptors by haloperidol (Gyertyán and Sághy, 2007; Millan et al., 1997; Shimizu et al., 2014) . Blockade of dopamine D 3 receptors has been reported to prevent the development of supersensitive to dopamine-like drug (Richtand et al., 2000) . Moreover, dopamine D 3 receptor knockout mice showed no supersensitivity to dopamine-like drugs and no elevation in the proportion of D 2 High receptors (Seeman, 2011) . Tokunaga et al. (2012) have shown that repeated administration of dopamine D 3 receptor agonists up-regulates dopamine D 2 receptor expression in the striatum. Blonanserin, unlike haloperidol, has high and comparable binding affinity for both dopamine D 2 and D 3 receptors (Baba et al., 2015; Richtand et al., 2007) , and hence is presumed unlikely to cause development of dopamine supersensitivity. This is probably due to its antagonistic activity for dopamine D 3 receptors. To test this hypothesis, we conducted quinpiroleinduced hyperlocomotion test in rats after continuous concomitant administration of haloperidol and the dopamine D 3 receptor antagonist PG-03017. Interestingly, PG-03017 prevented the development of supersensitivity to quinpirole in haloperidol-treated rats. These results support our hypothesis. However, further studies are needed to elucidate the mechanism of action underlying the beneficial effect of blonanserin.
Blonanserin is an oral preparation, and therefore it was orally administered to rats in this study. In contrast, Samaha et al. (2008) have shown that continuous haloperidol exposure in the brain by osmotic pump is more likely to induce dopamine supersensitivity than intermittent exposure by daily treatment. In this study, we were unable to use an osmotic pump for continuous administration of blonanserin due to poor solubility in the vehicle used for haloperidol. Thus, it is necessary to additionally assess continuous administration effects of blonanserin on dopamine supersensitivity after choosing an appropriate solvent. Moreover, a potential limitation of our findings is that the efficacy of blonanserin was evaluated at a single dose. Further assessment with different doses of blonanserin may determine its pharmacological properties.
Conclusions
The present study shows that, unlike haloperidol, repeated administration of blonanserin, at twice its ED 50 value, does not lead to supersensitivity to quinpirole, and but increases striatal dopamine D 2 receptors density in rats. These results suggest that the long-term treatment with blonanserin is unlikely to cause dopamine supersensitivity. We also showed in this study that the dopamine D 3 receptor antagonist PG-03017 prevents the development of supersensitivity to quinpirole in haloperidol-treated rats, suggesting that potent antagonism of blonanserin on dopamine D 3 receptors may be involved in its beneficial effect regarding dopamine supersensitivity.
